Avoro Capital Advisors LLC
About Avoro Capital Advisors LLC’s 13F portfolio
Avoro Capital Advisors LLC is an institutional investment manager that discloses its US-listed holdings each quarter through an SEC Form 13F filing. As of , Avoro Capital Advisors LLC reported $11.1B across 26 US-listed positions (). Its largest position is UNITED THERAPEUTICS CORP (UTHR) at 14% of the reported book, and its ten biggest holdings make up 79% of the portfolio. Browse every manager in the fund managers directory, or see the legendary investors we track on the superinvestors page.
| # | Stock | Price | % of portfolio | Shares | Value |
|---|---|---|---|---|---|
| 1 | NASDAQ: UTHR UNITED THERAPEUTICS CORP | $559.10 −3.16% | 14% | 2.8M | $1.5B |
| 2 | NASDAQ: ASND ASCENDIS PHARMA | $255.96 −5.32% | 12% | 5.1M | $1.4B |
| 3 | NASDAQ: KRYS KRYSTAL BIOTECH INC | $315.82 +0.15% | 9.6% | 2.9M | $1.1B |
| 4 | NASDAQ: MDGL MADRIGAL PHARMACEUTICALS INC | $396.74 −0.34% | 8.8% | 1.8M | $984.4M |
| 5 | NASDAQ: ARGX ARGENX SE | $942.04 +0.08% | 8.3% | 1.0M | $927.8M |
| 6 | NASDAQ: ARWR ARROWHEAD PHARMACEUTICALS INC | $43.65 +1.25% | 8.3% | 11.4M | $925.6M |
| 7 | NASDAQ: KYMR KYMERA THERAPEUTICS INC | $119.39 −1.44% | 7.7% | 7.5M | $857.1M |
| 8 | NASDAQ: RVMD REVOLUTION MEDICINES INC | $159.43 −0.24% | 3.9% | 2.3M | $430.2M |
| 9 | NASDAQ: CYTK CYTOKINETICS INC | $51.46 +0.27% | 3.8% | 5.0M | $425.9M |
| 10 | NASDAQ: CELC CELCUITY INC | $56.31 +1.28% | 3.2% | 3.4M | $355.7M |
| 11 | NASDAQ: GPCR STRUCTURE THERAPEUTICS INC | $17.12 −1.38% | 3.2% | 6.6M | $351.8M |
| 12 | NASDAQ: XENE XENON PHARMACEUTICALS INC | $37.56 −0.50% | 3.1% | 5.8M | $348.7M |
| 13 | NASDAQ: DFTX DEFINIUM THERAPEUTICS INC | — — | 3.0% | 7.2M | $338.2M |
| 14 | NASDAQ: QURE UNIQURE NV | $20.23 −0.34% | 2.8% | 6.7M | $309.9M |
| 15 | NASDAQ: VERA VERA THERAPEUTICS INC | $26.75 +4.57% | 2.2% | 5.7M | $245.6M |
| 16 | NASDAQ: TSHA TAYSHA GENE THERAPIES INC | $3.77 −5.51% | 1.5% | 23.9M | $162.7M |
| 17 | NASDAQ: OCUL OCULAR THERAPEUTIX INC | $5.86 −1.35% | 1.1% | 12.5M | $123.1M |
| 18 | NASDAQ: DMRA DAMORA THERAPEUTICS INC | — — | 0.9% | 3.8M | $98.4M |
| 19 | NASDAQ: COAG HEMAB THERAPEUTICS HLDGS INC | — — | 0.6% | 1.9M | $70.7M |
| 20 | NASDAQ: GHRS GH RESEARCH PLC | $18.56 +1.70% | 0.4% | 1.8M | $48.4M |
| 21 | NASDAQ: VRDN VIRIDIAN THERAPEUTICS INC | $31.44 +4.38% | 0.4% | 2.5M | $45.9M |
| 22 | NASDAQ: SEPN SEPTERNA INC | $39.20 −0.63% | 0.4% | 1.3M | $44.8M |
| 23 | NASDAQ: AVTX AVALO THERAPEUTICS | $6.75 +0.75% | 0.4% | 2.3M | $43.1M |
| 24 | NASDAQ: SNSE FAETH THERAPEUTICS INC | $25.96 −28.23% | 0.3% | 1.4M | $36.1M |
| 25 | NASDAQ: WHWK WHITEHAWK THERAPEUTICS INC | $3.12 −0.32% | 0.1% | 2.8M | $13.1M |
Showing 1–25 of 26 positions on this page reported in this 13F.
- Healthcare95%
- AddedUTHRUNITED THERAPEUTICS CORP+5.6%$1.5B
- NewASNDASCENDIS PHARMA—$1.4B
- AddedMDGLMADRIGAL PHARMACEUTICALS INC+0.8%$984.4M
- AddedARWRARROWHEAD PHARMACEUTICALS INC+6.1%$925.6M
- AddedCYTKCYTOKINETICS INC+50.0%$425.9M
- AddedCELCCELCUITY INC+0.7%$355.7M
- AddedDFTXDEFINIUM THERAPEUTICS INC+43.8%$338.2M
- AddedQUREUNIQURE NV+12.9%$309.9M
- AddedTSHATAYSHA GENE THERAPIES INC+10.1%$162.7M
- AddedOCULOCULAR THERAPEUTIX INC+1.8%$123.1M
- ReducedRVMDREVOLUTION MEDICINES INC−2.0%$430.2M
- ReducedVERAVERA THERAPEUTICS INC−2.8%$245.6M
- ReducedLXEOLEXEO THERAPEUTICS INC−20.6%$6.9M
- SoldASNDASCENDIS PHARMA−100%—
- SoldMNKDMANNKIND CORP−100%—
- SoldALKSALKERMES PLC−100%—
- SoldSLNOSOLENO THERAPEUTICS INC−100%—
- SoldTERNTERNS PHARMACEUTICALS INC−100%—
- SoldCNTACENTESSA PHARMACEUTICALS PLC−100%—
- SoldAPLSAPELLIS PHARMACEUTICALS INC−100%—
Companies where this manager has disclosed a stake of more than 5% of a class of shares, as reported to the SEC on Schedule 13D (activist) or 13G (passive). Figures are as disclosed in each filing — tap a date to open the source document.
| # | Stock | Type | % of class | Shares | Filed |
|---|---|---|---|---|---|
| 1 | SCTX Scribe Therapeutics, Inc. | 13D | 16.4% | 3.1M | Filed 30 JUL 2026 |
| 2 | CNTA Centessa Pharmaceuticals plc | 13G | 10.0% · 2 classes | 14.6M | Filed 17 FEB 2026 |
| 3 | — Tourmaline Bio, Inc. | 13G | 9.9% | 2.6M | Filed 14 AUG 2025 |
| 4 | ARWR Arrowhead Pharmaceuticals, Inc. | 13G | 9.6% · 2 classes | 13.8M | Filed 14 AUG 2026 |
| 5 | GPCR Structure Therapeutics Inc. | 13G | 9.4% | 16.2M | Filed 14 NOV 2025 |
| 6 | VERA Vera Therapeutics, Inc. | 13G | 8.9% · 2 classes | 5.6M | Filed 14 FEB 2025 |
| 7 | COAG Hemab Therapeutics Holdings, Inc. | 13G | 7.1% | 3.3M | Filed 14 AUG 2026 |
| 8 | DMRA Damora Therapeutics, Inc. | 13G | 6.3% | 3.8M | Filed 15 MAY 2026 |
| 9 | FTH Faeth Therapeutics, Inc. | 13G | 5.5% | 1.4M | Filed 16 NOV 2026 |
| 10 | DFTX Definium Therapeutics, Inc. | 13G | 5.1% | 5.0M | Filed 17 FEB 2026 |
Showing all 10 disclosed stakes. 2 last disclosed over a year ago (the holder may since have dropped below 5%).
Reading Avoro Capital Advisors LLC’s 13F portfolio
Avoro Capital Advisors LLC’s $11.1B 13F book is spread across 26 reported positions and is highly concentrated — its ten largest positions alone are 79% of the portfolio. A book this concentrated means a small group of names drives most of its performance. Its five largest positions are UTHR, ASND, KRYS, MDGL and ARGX, led by UNITED THERAPEUTICS CORP (UTHR) at 14% of the portfolio. The heaviest sector exposure is Healthcare (95%).
What Avoro Capital Advisors LLC changed last quarter
Between 2026-03-31 and Q2 2026, Avoro Capital Advisors LLC was a net buyer: it opened 3 new positions and added to 11 more, while trimming 3 and closing 7 outright. Against a 26-name book, that is high turnover, pointing to an active reshuffle of the book. Its largest new or increased position was UNITED THERAPEUTICS CORP (UTHR), and its biggest reduction was REVOLUTION MEDICINES INC (RVMD).
What a 13F does and doesn’t reveal
A 13F captures only Avoro Capital Advisors LLC’s long positions in US-listed stocks at a single quarter-end, so it is best read as a lagged snapshot rather than a live portfolio. It won’t show shorts, cash, bonds, or holdings listed outside the US, and it never reveals the price paid or the reasoning behind a trade. The signal is in the pattern over time: which names Avoro Capital Advisors LLC is building up, trimming, or exiting, and how concentrated the book stays from quarter to quarter.
Frequently asked questions
What is an SEC 13F filing?
A Form 13F is a report that every institutional investment manager with at least $100 million in US-listed securities must file with the SEC within 45 days of each quarter's end. It lists the manager's long positions in US-listed stocks and certain options, with the share count and market value of each. Avoro Capital Advisors LLC's profile on this page is built directly from those filings.
How current is the 13F data on Avoro Capital Advisors LLC's page?
It reflects Avoro Capital Advisors LLC's most recently filed 13F, currently the quarter ending Q2 2026. Because managers have up to 45 days after a quarter closes to file, a 13F is always a slightly lagged view rather than a live portfolio. When Avoro Capital Advisors LLC files its next quarterly report, this page refreshes automatically.
Can I see Avoro Capital Advisors LLC's complete list of holdings?
This page highlights Avoro Capital Advisors LLC's largest positions rather than all 26 names in the filing. The complete, position-by-position 13F is public and available from the SEC's EDGAR database under Avoro Capital Advisors LLC's filings.
Does a 13F show everything Avoro Capital Advisors LLC owns?
No. A 13F only covers long positions in US-listed stocks and certain options. It leaves out short positions, cash, bonds, commodities, foreign-listed stocks, and private holdings, so it is a partial view of Avoro Capital Advisors LLC's book rather than its full strategy or total assets.
Is 13F data investment advice?
No. Everything here is educational. 13F positions are disclosed with a delay, cover only long US-listed holdings, and never explain why Avoro Capital Advisors LLC made a trade or at what price. Treat it as a research lens, not a recommendation, and speak with a licensed financial advisor before making investment decisions.
Not investment advice. Holdings data comes from public SEC Form 13F filings, which are filed with a delay of up to 45 days and may be amended later. It describes historical, disclosed positions in US-listed securities only, meaning no shorts, cash, or foreign holdings, and it is not a recommendation. Always do your own research and speak with a licensed financial advisor before making investment decisions.

